Overall, these structural differences between antibodies to AChR and MuSK explain why complement inhibitors do not seem to be effective in MuSK antibody-mediated myasthenia gravis, which is predominantly an IgG4-driven process [34]. The gene discussed is MUSK; the disease is myasthenia gravis.